All filters
Slidesets
The prevalence of resistance associated substitutes through Europe The European prevalence of hepatitis C virus NS5A polymorphisms- Stephanie Popping
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
The current status of PrEP in Europe- Pep Coll, MD
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
Influence of resistance in the future- Richard Harrigan, MD
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
A 5 amino-acid insertion in the C-terminal region of HIV-2 integrase impacts phenotypic susceptibility to the five integrase inhibitors- Quentin Le Hingrat
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
A new wild-type HIV in the era of transmitted drug resistance- Kristof Theys, PhD
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
Resistance mutations to different classes of antiretroviral agents predict virological failure in HIV+ patients with low level viremia: a retrospective study from the ARCA cohort- Francesca Lombardi
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
Dynamics of therapy options for HIV-1 infected patients with historical multi-drug resistance (MDR), based on deep-sequencing of proviral DNA – First Results from the LOWER Study- Alexander Thielen
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
Factors associated with virological response and resistance profile in HIV-1 infected patients starting first-line integrase inhibitors based regimen in clinical settings- Maria Santoro
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
Mutations in the 3’-polypurine tract of HIV-1 point to a new integrase strand transfer inhibitor (INSTI) resistance mechanism in vivo- Jeroen van Kampen
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
Novel simplified bioinformatics for NGS data analysis- Marc Noguera-Julian, PhD
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
Management of hepatitis C therapy failures - clinical perspective- Sanjay Bhagani, BSc FRCP
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
Management of hepatitis C therapy failures - virological perspective- Francesca Ceccherini– Silberstein, PhD
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
Selection of fitness-associated substitutions in patients failing NS5A inhibitors based therapy : analysis of HCV full-length genome deep sequencing by means of shotgun metagenomics- Slim Fourati
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
Evaluation of pre-treatment risk factors associated with failure in HCVinfected patients naive to direct acting antivirals: particular focus on natural resistance- Silvia Barbaliscia
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
Acute hepatitis A to E, diagnosis and management - Thomas Berg, MD
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
B/F/TAF in treatment-naïve HIV-1 and HIV-1 RNA suppressed switch patients- Kirsten White, MD, PhD
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
Clinical development of ABX464, drug candidate for HIV functional cure- Jean-Marc Steens, MD
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
Reduced drug regimens- Andrea De Luca, MD
Presented at:
European Meeting on HIV & Hepatitis 2018
Slidesets
What is the place of the monoclonal antibodies in the clinic- Julià Blanco, PhD
Presented at:
European Meeting on HIV & Hepatitis 2018
Meeting
INTEREST 2018
Meeting
European HIV Clinical Forum 2017
Slidesets
State of the ART: Integrase Inhibitors Resistance- Charles Boucher, MD, PhD
Presented at:
European HIV Clinical Forum 2017
Slidesets
What is the virological support for reduced drug regimens?- Anne-Geneviève Marcelin, MD
Presented at:
European HIV Clinical Forum 2017
Slidesets
What is the clinical support for reduced drug regimens?- David Cooper, MD, DSc
Presented at:
European HIV Clinical Forum 2017